Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 14
- 13F valueReported value at the end of Q2 2026
- $105.1K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LIMN, Q2 2026
No superinvestor reported holding LIMN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Liminatus Pharma, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Liminatus Pharma, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Liminatus Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cygnus Capital Advisors, LLC | 329,333 | $36.0K | 0.02% | −20,667−5.9% | Reduced |
| XTX Topco Ltd | 221,839 | $24.5K | 0.00% | +221,839 | New |
| Geode Capital Management, LLC | 138,418 | $15.3K | 0.00% | +20,635+17.5% | Added |
| Citadel Advisors LLC | 56,089 | $6.19K | 0.00% | −621,429−91.7% | Reduced |
| Vanguard Capital Management LLC | 50,440 | $5.55K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 40,220 | $4.44K | 0.00% | +40,220 | New |
| StoneX Group Inc. | 26,058 | $3.93K | 0.00% | +26,058 | New |
| Vanguard Fiduciary Trust Co | 22,984 | $2.53K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 19,000 | $2.10K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 16,730 | $1.84K | 0.00% | −37,848−69.3% | Reduced |